Drug Detail:Suprax (Cefixime [ sef-ix-eem ])
Drug Class: Third generation cephalosporins
Highlights of Prescribing Information
SUPRAX® (cefixime) tablets, for oral use
SUPRAX® (cefixime) capsules, for oral use
SUPRAX® (cefixime) chewable tablets, for oral use
SUPRAX® (cefixime) for oral suspension
Initial U.S. Approval: 1986
Recent Major Changes
Warnings and Precautions, Risk in Patients with Phenylketonuria (5.6) 03/2017
Indications and Usage for Suprax
SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections:
- Uncomplicated Urinary Tract Infections (1.1)
- Otitis Media (1.2)
- Pharyngitis and Tonsillitis (1.3)
- Acute Exacerbations of Chronic Bronchitis (1.4)
- Uncomplicated Gonorrhea (cervical/urethral) (1.5)
To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.6)
Suprax Dosage and Administration
- Adults: 400 mg daily (2.1)
- Pediatric patients (6 months and older): 8 mg/kg/day (2.2)
Dosage Forms and Strengths
- Film-coated, scored Tablets: 400 mg (3)
- Capsules: 400 mg (3)
- Chewable Tablets: 100 mg, 150 mg and 200 mg (3)
- Oral Suspension: 100 mg/5 mL, 200 mg/5 mL and 500 mg/5 mL (3)
Contraindications
- Contraindicated in patients with known allergy to cefixime or other cephalosporins. (4)
Warnings and Precautions
- Hypersensitivity reactions including shock and fatalities have been reported with cefixime. Discontinue use if a reaction occurs. (5.1)
- Clostridium difficile associated diarrhea: Evaluate if diarrhea occurs. (5.2)
- Risk in Patients with Phenylketonuria (PKU): Before prescribing SUPRAX chewable tablets in a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including SUPRAX chewable tablets. (5.6)
Adverse Reactions/Side Effects
Most common adverse reactions are gastrointestinal such as diarrhea (16%), nausea (7%), loose stools (6%), abdominal pain (3%), dyspepsia (3%), and vomiting. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharma at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
- Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. (7.1)
- Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly with warfarin and anticoagulants. (7.2)
Use In Specific Populations
- Pregnancy: Cefixime should be used during pregnancy only if clearly needed. (8.1)
- Nursing Mothers: Consideration should be given to discontinuing nursing temporarily during treatment with cefixime. (8.3)
- Children: Efficacy and safety in infants aged less than six months have not been established. (8.4)
- Geriatric Use: Clinical studies did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. (8.5)
- Renal Impairment: Cefixime may be administered in the presence of impaired renal function. Dose adjustment is required in patients whose creatinine clearance is less than 60 mL/min. (8.6)
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 1/2020
Full Prescribing Information
1. Indications and Usage for Suprax
1.2 Otitis Media
Note: For patients with otitis media caused by Streptococcus pneumoniae, overall response was approximately 10% lower for cefixime than for the comparator [see Clinical Studies (14)].
2. Suprax Dosage and Administration
2.1 Adults
In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.
2.2 Pediatric Patients (6 months or older)
Note: A suggested dose has been determined for each pediatric weight range. Refer to Table 1. Ensure all orders that specify a dose in milliliters include a concentration, because SUPRAX for oral suspension is available in three different concentrations (100 mg/5 mL, 200 mg/5 mL, and 500 mg/5 mL).
|
|||||
| PEDIATRIC DOSAGE CHART
Doses are suggested for each weight range and rounded for ease of administration |
|||||
|
| SUPRAX (cefixime) for oral suspension
| SUPRAX (cefixime) chewable tablet
|
|||
|
| 100 mg/5 mL
| 200 mg/5 mL
| 500 mg/5 mL
|
|
|
| Patient Weight
(kg) | Dose/Day
(mg) | Dose/Day
(mL) | Dose/Day
(mL) | Dose/Day
(mL) | Dose
|
| 5 to 7.5*
| 50 | 2.5 | -- | -- | -- |
| 7.6 to 10*
| 80 | 4 | 2 | -- | -- |
| 10.1 to 12.5 | 100 | 5 | 2.5 | 1 | 1 tablet of 100 mg |
| 12.6 to 20.5 | 150 | 7.5 | 4 | 1.5 | 1 tablet of 150 mg |
| 20.6 to 28 | 200 | 10 | 5 | 2 | 1 tablet of 200 mg |
| 28.1 to 33 | 250 | 12.5 | 6 | 2.5 | 1 tablet of 100 mg and 1 tablet of 150 mg |
| 33.1 to 40 | 300 | 15 | 7.5 | 3 | 2 tablets of 150 mg |
| 40.1 to 45 | 350 | 17.5 | 9 | 3.5 | 1 tablet of 150 mg and 1 tablet of 200 mg |
| 45.1 or greater | 400 | 20 | 10 | 4 | 2 tablets of 200 mg |
Otitis media should be treated with the chewable tablets or suspension. Clinical trials of otitis media were conducted with the chewable tablets or suspension, and the chewable tablets or suspension results in higher peak blood levels than the tablet when administered at the same dose.
Therefore, the tablet or capsule should not be substituted for the chewable tablets or suspension in the treatment of otitis media [see Clinical Pharmacology (12.3)].
In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.
2.3 Renal Impairment
|
|||||
| Renal Dysfunction
| SUPRAX (cefixime) for oral suspension
| Tablet
| Chewable Tablet
|
||
| Creatinine Clearance (mL/min) | 100 mg/5 mL
| 200 mg/5 mL
| 500 mg/5 mL
| 400 mg
| 200 mg
|
|
| Dose/Day (mL) | Dose/Day (mL) | Dose/Day (mL) | Dose/Day | Dose/Day |
| 60 or greater | Normal dose | Normal dose | Normal dose | Normal dose | Normal dose |
| 21 to 59*
OR renal hemodialysis* | 13 | 6.5 | 2.6 | Not Appropriate | Not Appropriate |
| 20 or less OR continuous peritoneal dialysis | 8.6 | 4.4 | 1.8 | 0.5 tablet | 1 tablet |
2.4 Reconstitution Directions for Oral Suspension
| Strength
| Bottle Size
| Reconstitution Directions
|
| 100 mg/5 mL and 200 mg/5 mL | 100 mL | To reconstitute, suspend with 68 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
| 100 mg/5 mL and 200 mg/5 mL | 75 mL | To reconstitute, suspend with 51 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
| 100 mg/5 mL and 200 mg/5 mL | 50 mL | To reconstitute, suspend with 34 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
| 200 mg/5 mL | 37.5 mL | To reconstitute, suspend with 26 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
| 200 mg/5 mL | 25 mL | To reconstitute, suspend with 17 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
| 500 mg/5 mL | 20 mL | To reconstitute, suspend with 14 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
| 500 mg/5 mL | 10 mL | To reconstitute, suspend with 8 mL water. Method: Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. |
3. Dosage Forms and Strengths
SUPRAX is available for oral administration in the following dosage forms and strengths:
- Film-coated tablets provide 400 mg of cefixime as trihydrate. These are white to off-white, film-coated, capsule shaped tablets with beveled edges and a divided score line on each side. The tablet is debossed with "SUPRAX" across one side and "LUPIN" across the other side.
- Capsules provide 400 mg of cefixime as trihydrate. These are size "00EL" capsules with pink opaque cap and pink opaque body with "LU" on the cap and "U43" on the body in black ink. Capsules contain white to yellowish white granular powder.
- Chewable tablets provide either 100 mg or 150 mg or 200 mg of cefixime as trihydrate. The 100 mg tablet is pink, round tablet, debossed with "SUPRAX 100" on one side and "LUPIN" on other side. The 150 mg tablet is pink, round tablet, debossed with "SUPRAX 150" on one side and "LUPIN" on other side. The 200 mg tablet is pink, round tablet, debossed with "SUPRAX 200" on one side and "LUPIN" on other side.
- Powder for oral suspension, when reconstituted, provides either 100 mg/5 mL or 200 mg/5 mL or 500 mg/5 mL of cefixime as trihydrate. For 100 mg/5 mL and 200 mg/5 mL, the powder has an off white to pale yellow color and is strawberry flavored. For 500 mg/5 mL, the powder has an off white to cream color and is strawberry flavored.
5. Warnings and Precautions
5.1 Hypersensitivity Reactions
Before therapy with SUPRAX is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs. If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to SUPRAX occurs, discontinue the drug.
5.2 Clostridium difficile-Associated Diarrhea
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
6. Adverse Reactions/Side Effects
6.1 Clinical Trials Experience
The most commonly seen adverse reactions in U.S. trials of the tablet formulation were gastrointestinal events, which were reported in 30% of adult patients on either the twice daily or the once daily regimen. Five percent (5%) of patients in the U.S. clinical trials discontinued therapy because of drug-related adverse reactions. Individual adverse reactions included diarrhea 16%, loose or frequent stools 6%, abdominal pain 3%, nausea 7%, dyspepsia 3%, and flatulence 4%. The incidence of gastrointestinal adverse reactions, including diarrhea and loose stools, in pediatric patients receiving the suspension was comparable to the incidence seen in adult patients receiving tablets.
6.2 Post-marketing Experience
Gastrointestinal
Several cases of documented pseudomembranous colitis were identified in clinical trials. The onset of pseudomembranous colitis symptoms may occur during or after therapy.
Hypersensitivity Reactions
Anaphylactic/anaphylactoid reactions (including shock and fatalities), skin rashes, urticaria, drug fever, pruritus, angioedema, and facial edema. Erythema multiforme, Stevens-Johnson syndrome, and serum sickness-like reactions have been reported.
Hepatic
Transient elevations in SGPT, SGOT, alkaline phosphatase, hepatitis, jaundice.
Renal
Transient elevations in BUN or creatinine, acute renal failure.
Central Nervous System
Headaches, dizziness, seizures.
Hemic and Lymphatic System
Transient thrombocytopenia, leukopenia, neutropenia, prolongation in prothrombin time, elevated LDH, pancytopenia, agranulocytosis, and eosinophilia.
Abnormal Laboratory Tests
Hyperbilirubinemia.
Other Adverse Reactions
Genital pruritus, vaginitis, candidiasis, toxic epidermal necrolysis.
Adverse Reactions Reported for Cephalosporin-class Drugs
Allergic reactions, superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, and colitis.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced [see Dosage and Administration (2) and Overdosage (10)]. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
7. Drug Interactions
7.3 Drug/Laboratory Test Interactions
The administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®**, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix®** or TesTape®**) be used. A false-positive direct Coombs test has been reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug.
** Clinitest® and Clinistix® are registered trademarks of Ames Division, Miles Laboratories, Inc. Tes-Tape® is a registered trademark of Eli Lilly and Company.
8. Use In Specific Populations
8.1 Pregnancy
Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of harm to the fetus due to cefixime. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
11. Suprax Description
Molecular weight = 507.50 as the trihydrate. Chemical Formula is C16H15N5O7S2.3H2O
The structural formula for cefixime is:
- Inactive ingredients contained in SUPRAX® (cefixime) 400 mg tablets USP are: dibasic calcium phosphate, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, pregelatinized starch, titanium dioxide, and triacetin.
- Inactive ingredients contained in SUPRAX® (cefixime) 400 mg capsules are: colloidal silicon dioxide, crospovidone, low substituted hydroxy propyl cellulose, magnesium stearate, and mannitol. The capsule shell contains the following inactive ingredients: ferric oxide black, ferric oxide red, gelatin, potassium hydroxide, propylene glycol, shellac, sodium lauryl sulfate, and titanium dioxide.
- Inactive ingredients contained in SUPRAX® (cefixime) 100 mg or 150 mg or 200 mg chewable tablets are: aspartame, colloidal silicon dioxide, crospovidone, FD&C Red # 40 Aluminium Lake, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, fantasy flavor permaseal, and tutti frutti flavor.
- Inactive ingredients contained in SUPRAX® (cefixime) powder for oral suspension USP are: colloidal silicon dioxide, sodium benzoate, strawberry flavor, sucralose (only in 500 mg/5 mL strength), sucrose, and xanthan gum.
12. Suprax - Clinical Pharmacology
12.1 Mechanism of Action
Cefixime is a semisynthetic cephalosporin antibacterial drug [see Microbiology (12.4)].
12.3 Pharmacokinetics
SUPRAX chewable tablets are bioequivalent to oral suspension.
SUPRAX tablets and suspension, given orally, are about 40% to 50% absorbed whether administered with or without food; however, time to maximal absorption is increased approximately 0.8 hours when administered with food. A single 200 mg tablet of cefixime produces an average peak serum concentration of approximately 2 mcg/mL (range 1 to 4 mcg/mL); a single 400 mg tablet produces an average peak concentration of approximately 3.7 mcg/mL (range 1.3 to 7.7 mcg/mL). The oral suspension produces average peak concentrations approximately 25% to 50% higher than the tablets, when tested in normal adult volunteers. Two hundred and 400 mg doses of oral suspension produce average peak concentrations of 3 mcg/mL (range 1 to 4.5 mcg/mL) and 4.6 mcg/mL (range 1.9 to 7.7 mcg/mL), respectively, when tested in normal adult volunteers. The area under the time versus concentration curve (AUC) is greater by approximately 10% to 25% with the oral suspension than with the tablet after doses of 100 to 400 mg, when tested in normal adult volunteers. This increased absorption should be taken into consideration if the oral suspension is to be substituted for the tablet. Because of the lack of bioequivalence, tablets should not be substituted for oral suspension in the treatment of otitis media [see Dosage and Administration (2)]. Cross-over studies of tablet versus suspension have not been performed in children.
The 400 mg capsule is bioequivalent to the 400 mg tablet under fasting conditions. However, food reduces the absorption following administration of the capsule by approximately 15% based on AUC and 25% based on Cmax.
Peak serum concentrations occur between 2 and 6 hours following oral administration of a single 200 mg tablet, a single 400 mg tablet or 400 mg of cefixime suspension. Peak serum concentrations occur between 2 and 5 hours following a single administration of 200 mg of suspension. Peak serum concentrations occur between 3 and 8 hours following oral administration of a single 400 mg capsule.
Distribution
Serum protein binding is concentration independent with a bound fraction of approximately 65%. In a multiple dose study conducted with a research formulation which is less bioavailable than the tablet or suspension, there was little accumulation of drug in serum or urine after dosing for 14 days. Adequate data on CSF levels of cefixime are not available.
Metabolism and Excretion
There is no evidence of metabolism of cefixime in vivo. Approximately 50% of the absorbed dose is excreted unchanged in the urine in 24 hours. In animal studies, it was noted that cefixime is also excreted in the bile in excess of 10% of the administered dose. The serum half-life of cefixime in healthy subjects is independent of dosage form and averages 3 to 4 hours but may range up to 9 hours in some normal volunteers.
Special Populations
Geriatrics: Average AUCs at steady state in elderly patients are approximately 40% higher than average AUCs in other healthy adults. Differences in the pharmacokinetic parameters between 12 young and 12 elderly subjects who received 400 mg of cefixime once daily for 5 days are summarized as follows:
|
||
| Pharmacokinetic Parameters (mean ± SD) for Cefixime in Both Young & Elderly Subjects
|
||
| Pharmacokinetic parameter
| Young
| Elderly
|
| Cmax (mg/L) | 4.74 ± 1.43 | 5.68 ± 1.83 |
| Tmax (h)*
| 3.9 ± 0.3 | 4.3 ± 0.6 |
| AUC (mg.h/L)*
| 34.9 ± 12.2 | 49.5 ± 19.1 |
| T½ (h)*
| 3.5 ± 0.6 | 4.2 ± 0.4 |
| Cave (mg/L)*
| 1.42 ±0.50 | 1.99 ± 0.75 |
However, these increases were not clinically significant [see Dosage and Administration (2)].
Renal Impairment: In subjects with moderate impairment of renal function (20 to 40 mL/min creatinine clearance), the average serum half-life of cefixime is prolonged to 6.4 hours. In severe renal impairment (5 to 20 mL/min creatinine clearance), the half-life increased to an average of 11.5 hours. The drug is not cleared significantly from the blood by hemodialysis or peritoneal dialysis. However, a study indicated that with doses of 400 mg, patients undergoing hemodialysis have similar blood profiles as subjects with creatinine clearances of 21 to 60 mL/min.
12.4 Microbiology
As with other cephalosporins, the bactericidal action of cefixime results from inhibition of cell wall synthesis. Cefixime is stable in the presence of certain beta-lactamase enzymes. As a result, certain organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases may be susceptible to cefixime.
Resistance
Resistance to cefixime in isolates of Haemophilus influenzae and Neisseria gonorrhoeae is most often associated with alterations in penicillin-binding proteins (PBPs). Cefixime may have limited activity against Enterobacteriaceae producing extended spectrum beta-lactamases (ESBLs). Pseudomonas species, Enterococcus species, strains of Group D streptococci, Listeria monocytogenes, most strains of staphylococci (including methicillin-resistant strains), most strains of Enterobacter species, most strains of Bacteroides fragilis, and most strains of Clostridium species are resistant to cefixime.
Antimicrobial Activity
Cefixime has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)].
Gram-positive Bacteria
Streptococcus pneumoniae
Streptococcus pyogenes
Gram-negative Bacteria
Escherichia coli
Haemophilus influenzae
Moraxella catarrhalis
Neisseria gonorrhoeae
Proteus mirabilis
The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefixime against isolates of similar genus or organism group. However, the efficacy of cefixime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.
Gram-positive Bacteria
Streptococcus agalactiae
Gram-negative Bacteria
Citrobacter amalonaticus
Citrobacter diversus
Haemophilus parainfluenzae
Klebsiella oxytoca
Klebsiella pneumoniae
Pasteurella multocida
Proteus vulgaris
Providencia species
Salmonella species
Serratia marcescens
Shigella species
Susceptibility Testing
For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
14. Clinical Studies
The overall response rate of Streptococcus pneumoniae to cefixime was approximately 10% lower and that of Haemophilus influenzae or Moraxella catarrhalis approximately 7% higher (12% when beta-lactamase positive isolates of H. influenzae are included) than the response rates of these organisms to the active control drugs.
In these studies, patients were randomized and treated with either cefixime at dose regimens of 4 mg/kg twice a day or 8 mg/kg once a day, or with a comparator. Sixty-nine to 70% of the patients in each group had resolution of signs and symptoms of otitis media when evaluated 2 to 4 weeks post-treatment, but persistent effusion was found in 15% of the patients. When evaluated at the completion of therapy, 17% of patients receiving cefixime and 14% of patients receiving effective comparative drugs (18% including those patients who had Haemophilus influenzae resistant to the control drug and who received the control antibacterial drug) were considered to be treatment failures. By the 2 to 4 week follow-up, a total of 30%-31% of patients had evidence of either treatment failure or recurrent disease.
|
(a)Number eradicated/number isolated. |
|||
|
(b)An additional 20 beta-lactamase positive isolates of Haemophilus influenzae were isolated, but were excluded from this analysis because they were resistant to the control antibacterial drug. In nineteen of these, the clinical course could be assessed and a favorable outcome occurred in 10. When these cases are included in the overall bacteriological evaluation of therapy with the control drugs, 140/185 (76%) of pathogens were considered to be eradicated. |
|||
| Bacteriological Outcome of Otitis Media at Two to Four Weeks Post-Therapy Based on Repeat Middle Ear Fluid Culture or Extrapolation from Clinical Outcome
|
|||
| Organism
| Cefixime(a)
4 mg/kg BID | Cefixime(a)
8 mg/kg QD | Control(a)
drugs |
| Streptococcus pneumoniae
| 48/70 (69%) | 18/22 (82%) | 82/100 (82%) |
| Haemophilus influenzae
beta-lactamase negative | 24/34 (71%) | 13/17 (76%) | 23/34 (68%) |
| Haemophilus influenzae
beta-lactamase positive | 17/22 (77%) | 9/12 (75%) | 1/1 (b) |
| Moraxella catarrhalis
| 26/31 (84%) | 5/5 | 18/24 (75%) |
| S. pyogenes
| 5/5 | 3/3 | 6/7 |
| All Isolates | 120/162 (74%) | 48/59 (81%) | 130/166 (78%) |
16. How is Suprax supplied
| Dosage Form
| Strength
| Description
| Package Size
| NDC Code
| Storage
|
|
|
| White to off-white, film-coated, capsule shaped tablets with beveled edges and | Bottles of 10 tablets | 27437-201-10 |
|
| SUPRAX® (cefixime) tablets USP
| 400 mg | a divided score line on each side, debossed with “SUPRAX” across one side | Bottle of 50 tablets | 27437-201-08 | Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. |
|
|
| and “LUPIN” across other side, containing 400 mg of cefixime as the trihydrate. | Bottle of 100 tablets | 27437-201-01 |
|
| SUPRAX® (cefixime) capsules
| 400 mg | Size “00EL” capsules with pink opaque cap and pink opaque body, imprinted with “LU” on cap and “U43” on body in black | Bottle of 50 capsules | 27437-208-08 | Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. |
|
|
| ink, containing white to yellowish white granular powder containing 400 mg of cefixime as the trihydrate. | Unit Dose Package of 10 (1 blister of 10 capsules) | 27437-208-11 |
|
|
|
|
| Bottles of 10 tablets | 27437-203-10 |
|
|
| 100 mg | Pink, round tablet, debossed with “SUPRAX 100” on one side and “LUPIN” on other side. | Bottle of 50 tablets | 27437-203-08 |
|
|
|
|
| Unit Dose Package of 10 (1 blister of 10 tablets) | 27437-203-11 |
|
|
|
|
| Bottles of 10 tablets | 27437-204-10 |
|
| SUPRAX® (cefixime) chewable tablets
| 150 mg | Pink, round tablet, debossed with “SUPRAX 150” on one side and “LUPIN” on other side. | Bottle of 50 tablets | 27437-204-08 | Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. |
|
|
|
| Unit Dose Package of 10 (1 blister of 10 tablets) | 27437-204-11 |
|
|
|
|
| Bottles of 10 tablets | 27437-205-10 |
|
|
| 200 mg | Pink, round tablet, debossed with “SUPRAX 200” on one side and “LUPIN” on other side. | Bottle of 50 tablets | 27437-205-08 |
|
|
|
|
| Unit Dose Package of 10 (1 blister of 10 tablets) | 27437-205-11
|
|
|
|
| Off-white to pale yellow colored powder. After reconstituted as | Bottle of 50 mL | 68180-202-03 | |
|
| 100 mg/5 mL | directed, each 5 mL of reconstituted suspension contains 100 mg of | Bottle of 75 mL | 68180-202-02 | |
|
|
| cefixime as the trihydrate. | Bottle of 100 mL | 68180-202-01 |
|
|
|
|
| Bottle of 25 mL | 27437-206-05 |
|
|
|
|
| Bottle of 37.5 mL | 27437-206-06 | Prior to reconstitution: Store drug powder at |
| SUPRAX® (cefixime) for oral suspension USP
| 200 mg/5 mL | Off-white to pale yellow colored powder. After reconstituted as directed, each 5 mL of | Bottle of 50 mL | 27437-206-03 | 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. |
|
|
| reconstituted suspension contains 200 mg of cefixime as the trihydrate. | Bottle of 75 mL | 27437-206-02 | After reconstitution: Store at room temperature or under refrigeration. Keep tightly closed. |
|
|
|
| Bottle of 100 mL | 27437-206-01 |
|
|
| 500 mg/5 mL | Off white to cream colored powder forming off-white to pale yellow suspension with characteristic fruity odor | Bottle of 10 mL | 27437-207-02 |
|
|
|
| on constitution. After reconstituted as directed, each mL of reconstituted suspension contains 100 mg of cefixime as the trihydrate. | Bottle of 20 mL | 27437-207-03 |
|
17. Patient Counseling Information
17.1 Information for Patients
Counsel patients with phenylketonuria that SUPRAX chewable tablets contain aspartame, a source of phenylalanine as follows: Each SUPRAX chewable tablet contains 3.3 mg, 5 mg and 6.7 mg of phenylalanine per 100 mg, 150 mg and 200 mg strength, respectively.
Advise patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible.
| Products
| Manufactured for:
| Manufactured by:
|
| SUPRAX ® (cefixime) tablets, 400 mg | ||
| SUPRAX ® (cefixime) capsules, 400 mg | ||
| SUPRAX ® (cefixime) chewable tablets, 100 mg, 150 mg and 200 mg | Lupin Pharma
Baltimore, Maryland 21202 United States. | |
| SUPRAX ® (cefixime) for oral suspension, 200 mg/5 mL | Lupin Limited
Mandideep 462 046 India. |
|
| SUPRAX ® (cefixime) for oral suspension, 500 mg/5 mL | ||
| SUPRAX ® (cefixime) for oral suspension, 100 mg/5 mL | Lupin Pharmaceuticals, Inc.
Baltimore, Maryland 21202 United States |
| SUPRAX
cefixime powder, for suspension |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
| Labeler - Lupin Pharmaceuticals, Inc. (089153071) |
| Registrant - LUPIN LIMITED (675923163) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| LUPIN LIMITED | 725504448 | MANUFACTURE(68180-202) | |
